ATXN10

Across TCGA pan-cancer cohorts, ATXN10 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATXN10 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATXN10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATXN10 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where ATXN10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	15	view →
PDAC	OS	Quartile	III,IV	0.165	0.683	.010	15	view →
HNSC	DFS	Median	IV	0.671	0.921	.010	7	view →
LUAD	OS	Median	III,IV	1.000	0.663	.007	5	view →
UCEC	OS	Median	All	0.859	0.965	.039	4	view →
GBM	OS	Median	All	0.624	0.452	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATXN10–CCRCC (OS)

Open the CCRCC breakdown →